Quick Answer
GeneDx Holdings Corp. reported Gross Profit of $298.17 million for the year ending 2025.
- GeneDx Holdings Corp. showed an increase of +53.4% in Gross Profit from 2024 to 2025.
- This data is from GeneDx Holdings Corp.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $9.52 million | Q2 2020: -$4.40 million | Q3 2020: $4.59 million | Q4 2020: -$5.67 million | Q1 2021: -$4.32 million | Q2 2021: -$1.16 million | Q3 2021: -$8.31 million | Q4 2021: -$2.81 million | Q1 2022: $5.63 million | Q2 2022: -$29.60 million | Q3 2022: $13.55 million | Q1 2023: $15.24 million | Q2 2023: $18.76 million | Q3 2023: $25.26 million | Q1 2024: $37.41 million | Q2 2024: $42.95 million | Q3 2024: $47.83 million | Q1 2025: $58.48 million | Q2 2025: $70.90 million | Q3 2025: $84.53 million.
- Over the full 7 years of available data (2019 to 2025), GeneDx Holdings Corp.'s Gross Profit has grown by 260.2%.
- Historical annual values: Fiscal year 2025: $298.17 million | Fiscal year 2024: $194.40 million | Fiscal year 2023: $90.01 million | Fiscal year 2022: -$26.75 million | Fiscal year 2021: -$16.60 million | Fiscal year 2020: $4.03 million | Fiscal year 2019: $82.79 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: